Endocrine Abstracts

Introduction: The current UK guidelines (NICE TA791) recommend the use of romosozumab, a monoclonal sclerostin inhibitor, for patients at high imminent risk of fragility fractures. However, elderly patients with a very high risk of fractures often exhibit frailty and other comorbidities. This retrospective survey was conducted in a major trauma centre in northern England to evaluate the potential utilisation of romosozumab in a real-world setting.<p class=...